Toru Yamamoto

Dr. Toru Yamamoto

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YKYoshihiro Kitaoka
Yoshihiro Kitaoka
TUToshihiro Uchihashi
Toshihiro Uchihashi
SKSo Kawata
So Kawata
ANAkira Nishiura
Akira Nishiura
TYToru Yamamoto
Toru Yamamoto
SSSoju Seki
Soju Seki
Neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), present significant challenges owing to their complex pathologies and a lack of curative treatments. Early detection and reliable biomarkers are critical but remain elusive. Artificial intelligence (AI) has emerged as a transformative tool, enabling advancements in biomarker discovery, diagnostic accuracy, and therapeutic development. From optimizing clinical-trial designs to leveraging omics and neuroimaging data, AI facilitates understanding of disease and treatment innovation. Notably, technologies such as AlphaFold and deep learning models have revolutionized proteomics and neuroimaging, offering unprecedented insights into ALS pathophysiology. This review highlights the intersection of AI and ALS, exploring the current state of progress and future therapeutic prospects.

1 April 2001 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
TYToru Yamamoto
Toru Yamamoto
SNSadahiko Nishizawa
Sadahiko Nishizawa
Ichiro MaruyamaIchiro Maruyama
Ichiro Maruyama
MYMasanori Yoshida
Masanori Yoshida
TTTatsuro Tsuchida
Tatsuro Tsuchida
HIHarumi Itoh
Harumi Itoh

1 January 2025 in Journal of Dental Anesthesia and Pain Medicine
Verified
Journal Article
Open access
PDF file
TYToru Yamamoto
Toru Yamamoto
TITakutoshi Inoue
Takutoshi Inoue
NKNaotaka Kishimoto
Naotaka Kishimoto
KSKenji Seo
Kenji Seo
Yamamoto T, et al. J Dent Anesth Pain Med. 2025 Feb;25(1):15-22. https://doi.org/10.17245/jdapm.2025.25.1.15

26 August 2022 in Journal of Dental Sciences
Verified
Journal Article
Open access
TYToru Yamamoto
Toru Yamamoto
YKYuhei Koyama
Yuhei Koyama
TUTomoaki Ujita
Tomoaki Ujita
ESEmi Sawada
Emi Sawada
NKNaotaka Kishimoto
Naotaka Kishimoto
KSKenji Seo
Kenji Seo
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections can cause loss or alteration of taste and smell as early symptoms or sequelae, but the detailed mechanism behind this phenomenon remains unclear. Here, we investigated whether the SARS-CoV-2 spike protein induces taste cell apoptosis and expression of the apoptosis-related cytokine TNF-α in male Sprague–Dawley rats. Terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP)-fluorescein nick end labeling (TUNEL) assay results revealed a significantly higher apoptosis index for taste cells in the SARS-CoV-2 group than for those in the control group. An immunohistochemistry analysis indicated significantly more TNF-α-positive cells in the SARS-CoV-2 group compared with the control group. These data suggest that the SARS-CoV-2 spike protein promotes taste cell apoptosis and the release of apoptosis-related cytokine TNF-α, implicating its contribution to the taste malfunction caused by coronavirus disease 2019 (COVID-19).

1 December 1995 in Neurology
Verified
Journal Article
Closed access
PDF file
TYToru Yamamoto
Toru Yamamoto

1 January 2024 in Journal of Dental Anesthesia and Pain Medicine
Verified
Journal Article
Open access
PDF file
TITakutoshi Inoue
Takutoshi Inoue
TYToru Yamamoto
Toru Yamamoto
Inoue T, et al. J Dent Anesth Pain Med. 2024 Aug;24(4):297-299. https://doi.org/10.17245/jdapm.2024.24.4.297